The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells
Open accessAbstract
Dasatinib is a pharmacologic switch for CARs that enables physicians to control CAR T cell function in real time.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
ROR1 is expressed on many epithelial tumors and is a target for CAR T cells.
“the orphan receptor ROR1 is expressed on many epithelial tumors and is also a target for CAR T cells32,43.”
From Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer (2021) · cites this paper as [43]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688 · see citing works
Self-citationChimeric antigen receptor T-cell therapy—assessment and management of toxicities
Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., Daver, N., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.148 · Cited by 2,438 · see citing works
Chimeric Antigen Receptor Therapy
June, C. H., & Sadelain, M. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1706169 · Cited by 2,355 · see citing works
Self-citationTargeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S. J. C., Hamieh, M., Cunanan, K. M., Odak, A., Gönen, M., & Sadelain, M. (2017) · Nature · doi:10.1038/nature21405 · Cited by 1,831 · see citing works
Self-citationNorelli, M., Camisa, B., Barbiera, G., Falcone, L., Purevdorj, A., Genua, M., Sanvito, F., Ponzoni, M., Doglioni, C., Cristofori, P., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0036-4 · Cited by 1,406 · see citing works
CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
Giavridis, T., van der Stegen, S. J. C., Eyquem, J., Hamieh, M., Piersigilli, A., & Sadelain, M. (2018) · Nature Medicine · doi:10.1038/s41591-018-0041-7 · Cited by 1,272 · see citing works
Self-citationHSV-TK Gene Transfer into Donor Lymphocytes for Control of Allogeneic Graft-Versus-Leukemia
Bonini, C., Ferrari, G., Verzeletti, S., Servida, P., Zappone, E., Ruggieri, L., Ponzoni, M., Rossini, S., Mavilio, F., Traversari, C., et al. (1997) · Science · doi:10.1126/science.276.5319.1719 · Cited by 1,158 · see citing works
Hay, K. A., Hanafi, L.-A., Li, D., Gust, J., Liles, W. C., Wurfel, M. M., López, J. A., Chen, J., Chung, D., Harju-Baker, S., et al. (2017) · Blood · doi:10.1182/blood-2017-06-793141 · Cited by 1,156 · see citing works
Turtle, C. J., Hanafi, L.-A., Berger, C., Hudecek, M., Pender, B., Robinson, E., Hawkins, R., Chaney, C., Cherian, S., Chen, X., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf8621 · Cited by 1,016 · see citing works
Chromatin states define tumour-specific T cell dysfunction and reprogramming
Philip, M., Fairchild, L., Sun, L., Horste, E. L., Camara, S., Shakiba, M., Scott, A. C., Viale, A., Lauer, P., Merghoub, T., et al. (2017) · Nature · doi:10.1038/nature22367 · Cited by 933 · see citing works
Therapeutic T cell engineering
Sadelain, M., Rivière, I., & Riddell, S. R. (2017) · Nature · doi:10.1038/nature22395 · Cited by 886 · see citing works
Self-citationGeneration of Destabilized Green Fluorescent Protein as a Transcription Reporter
Li, X., Zhao, X., Fang, Y., Jiang, X., Duong, T., Fan, C., Huang, C.-C., & Kain, S. R. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.52.34970 · Cited by 846 · see citing works
An inducible caspase 9 safety switch for T-cell therapy
Straathof, K. C. M., Pulè, M. A., Yotnda, P., Dotti, G., Vanin, E. F., Brenner, M. K., Heslop, H. E., Spencer, D. M., & Rooney, C. M. (2005) · Blood · doi:10.1182/blood-2004-11-4564 · Cited by 745 · see citing works
Tokarski, J. S., Newitt, J. A., Chang, C. Y. J., Cheng, J. D., Wittekind, M. G., Kiefer, S. E., Kish, K., Lee, F. Y., Borzilleri, R. M., Lombardo, L. J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4187 · Cited by 698 · see citing works
Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency
Feucht, J., Sun, J., Eyquem, J., Ho, Y.-J., Zhao, Z., Leibold, J., Dobrin, A., Cabriolu, A., Hamieh, M., & Sadelain, M. (2019) · Nature Medicine · doi:10.1038/s41591-018-0290-5 · Cited by 547 · see citing works
Self-citationHudecek, M., Sommermeyer, D., Kosasih, P. L., Silva-Benedict, A., Liu, L., Rader, C. M., Jensen, M. C., & Riddell, S. R. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0127 · Cited by 534 · see citing works
Self-citationTargeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia
Paszkiewicz, P. J., Fräßle, S. P., Srivastava, S., Sommermeyer, D., Hudecek, M., Drexler, I., Sadelain, M., Liu, L., Jensen, M. C., Riddell, S. R., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84813 · Cited by 277 · see citing works
Self-citationMetabolism and disposition of dasatinib after oral administration to humans
Christopher, L. J., Cui, D., Wu, C., Luo, R., Manning, J. A., Bonacorsi, S. J., Lago, M., Allentoff, A., Lee, F. Y. F., McCann, B., et al. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.018267 · Cited by 202 · see citing works
Terakura, S., Yamamoto, T. N., Gardner, R., Turtle, C. J., Jensen, M. C., & Riddell, S. R. (2011) · Blood · doi:10.1182/blood-2011-07-366419 · Cited by 196 · see citing works
Kamath, A. V., Wang, J., Lee, F., & Marathe, P. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0478-8 · Cited by 189 · see citing works
Brandl, C., Haas, C., d’Argouges, S., Fisch, T., Kufer, P., Brischwein, K., Prang, N. S., Bargou, R. C., Suzich, J., Baeuerle, P. A., et al. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0298-z · Cited by 136 · see citing works
Blake, S. J., Hughes, T. P., Mayrhofer, G., & Lyons, A. B. (2008) · Clinical Immunology · doi:10.1016/j.clim.2008.02.006 · Cited by 112 · see citing works
Serafini, M., Manganini, M., Borleri, G., Bonamino, M., Imberti, L., Biondi, A., Golay, J., Rambaldi, A., & Introna, M. (2004) · Human Gene Therapy · doi:10.1089/10430340460732463 · Cited by 110 · see citing works
Evaluation of Intracellular Signaling Downstream Chimeric Antigen Receptors
Karlsson, H., Svensson, E., Gigg, C., Jarvius, M., Olsson‐Strömberg, U., Savoldo, B., Dotti, G., & Loskog, A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0144787 · Cited by 110 · see citing works
Chimeric Antigen Receptor Library Screening Using a Novel NF-κB/NFAT Reporter Cell Platform
Rydzek, J., Nerreter, T., Peng, H., Jutz, S., Leitner, J. M., Steinberger, P., Einsele, H., Rader, C. M., & Hudecek, M. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.11.015 · Cited by 54 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
CAR-T cell therapy: current limitations and potential strategies
Sterner, R. C., & Sterner, R. M. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00459-7 · Cited by 2,926 · see citing works
Recent advances and discoveries in the mechanisms and functions of CAR T cells
Larson, R. C., & Maus, M. V. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00323-z · Cited by 852 · see citing works
Luu, M., Riester, Z., Baldrich, A., Reichardt, N., Yuille, S., Busetti, A., Klein, M., Wempe, A., Leister, H., Raifer, H., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24331-1 · Cited by 771 · see citing works
Self-citationDufva, O., Koski, J., Maliniemi, P., Ianevski, A., Klievink, J., Leitner, J., Pölönen, P., Hohtari, H., Saeed, K., Hannunen, T., et al. (2020) · Blood · doi:10.1182/blood.2019002121 · Cited by 224 · see citing works
Weber, E. W., Lynn, R. C., Parker, K. R., Anbunathan, H., Lattin, J., Sotillo, E., Good, Z., Malipatlolla, M., Xu, P., Vandris, P., et al. (2020) · doi:10.1101/2020.01.26.920496 · Cited by 18 · see citing works
“Reinvigoration of exhausted CAR-T cells using the Src kinase inhibitor dasatinib We and others recently demonstrated that dasatinib, an FDA-approved tyrosine kinase inhibitor, suppresses CAR-T cell activation via rapid and reversible antagonism of proximal T cell receptor (TCR) signaling kinases (Mestermann et al., 20…”
BackgroundMethodInfluentialProtein kinase inhibitors as therapeutics in neurodegenerative and psychiatric disorders
Tridente, G., Jana, A., Nath, A., & Ashraf, G. M. (2023) · Receptor Tyrosine Kinases in Neurodegenerative and Psychiatric Disorders · doi:10.1016/b978-0-443-18677-6.00015-4 · Cited by 8 · see citing works
- Authors
- Mestermann, K., Giavridis, T., Weber, J., Rydzek, J., Frenz, S., Nerreter, T., Mades, A., Sadelain, M., Einsele, H., & Hudecek, M.
- Affiliations
- Universitätsklinikum Würzburg (DE)
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Hudecek, Michael
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2019-07-03
- Volume
- 11
- Issue
- 499
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC7523030
- OpenAlex
- W2956092422
- Cited by
- 531
- References
- 25
- Citations by year
- 2026: 62 · 2025: 61 · 2024: 82 · 2023: 77 · 2022: 84 · 2021: 75 · 2020: 76 · 2019: 14
- FWCI
- 25.98
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Alexander S. Onassis Public Benefit Foundation
- Deutsche Krebshilfe (313100)
- Interdisziplinäres Zentrum für Klinische Forschung, Universitätsklinikum Würzburg (Z4/109 and D-244)
- MSK Cancer Center (P30 CA008748)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- dasatinib, chimeric antigen receptor T cells, tyrosine kinase inhibitors, cytokine release syndrome, CAR T cell cytotoxicity, cytokine production, T cell proliferation, dose titration, antitumor immunity
- MeSH terms
- Dasatinib, Cytokine Release Syndrome, Animals, Dexamethasone, Female, Humans, Lymphocyte Activation, Phosphorylation, Receptors, Antigen, T-Cell, T-Lymphocytes, Mice, SCID, Lymphocyte Specific Protein Tyrosine Kinase p56(lck), Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
